In a phase 2 trial of 62 patients aged 12+ with asthma and ABPA, dupilumab improved pre-bronchodilator FEV1 at 24 weeks vs placebo (difference 0.201 L; P=.002). A 55.2% fall in severe exacerbations was not statistically significant (nominal P=.0627).
RCTn = 62
Bourdin et al. Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis